{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=8", "query": { "intervention": "Trametinib", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 180, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Trametinib&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T05:16:04.996Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01902173", "title": "Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" }, { "name": "Uprosertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2013-10-08", "completion_date": "2023-12-23", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01902173" }, { "nct_id": "NCT03704688", "title": "Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "KRAS Gene Mutation" ], "interventions": [ { "name": "Trametinib 0.5 mg", "type": "DRUG" }, { "name": "Trametinib 1 MG", "type": "DRUG" }, { "name": "Trametinib 1.5 MG", "type": "DRUG" }, { "name": "Trametinib 2 mg", "type": "DRUG" }, { "name": "Ponatinib 15 MG", "type": "DRUG" }, { "name": "Ponatinib 30 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 12, "start_date": "2018-10-09", "completion_date": "2022-02-04", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704688" }, { "nct_id": "NCT03148275", "title": "Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Epithelioid Hemangioendothelioma", "Metastatic Epithelioid Hemangioendothelioma", "Unresectable Epithelioid Hemangioendothelioma" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 44, "start_date": "2017-06-20", "completion_date": "2023-06-23", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03148275" }, { "nct_id": "NCT03455764", "title": "MCS110 With BRAF/MEK Inhibition in Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MCS110", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-09-10", "completion_date": "2023-09-05", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455764" }, { "nct_id": "NCT01723202", "title": "Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Thyroid Cancer", "Insular Thyroid Cancer", "Papillary Thyroid Cancer", "Recurrent Thyroid Cancer" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bhavana Konda", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2012-11-07", "completion_date": "2022-04-15", "has_results": true, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 5, "location_summary": "San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01723202" }, { "nct_id": "NCT03975231", "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRAF NP_004324.2:p.V600E", "BRAF V600K Mutation Present", "Thyroid Gland Anaplastic Carcinoma" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-14", "completion_date": "2027-10-05", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 3, "location_summary": "Duarte, California • Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975231" }, { "nct_id": "NCT02296112", "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "trametinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2015-01", "completion_date": "2021-04-16", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296112" }, { "nct_id": "NCT06582745", "title": "Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Langerhans Cell Histiocytosis" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cook Children's Health Care System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 75, "start_date": "2024-06-24", "completion_date": "2039-12", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06582745" }, { "nct_id": "NCT02196181", "title": "Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Unresectable Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2014-09-19", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 752, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 464 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02196181" }, { "nct_id": "NCT01990196", "title": "Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "degarelix", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2014-09-23", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-22T05:16:04.996Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01990196" } ] }